[zanpar321]

Intranasal GDNF delivery appears to have the potential to reverse PD symptoms! Why isn't this being fast tracked?

http://www.northeastern.edu/news/in-...gene-delivery/

https://www.michaeljfox.org/foundati...p?grant_id=511

http://www.northeastern.edu/news/201...nt-parkinsons/

[anagirl]

I think it is on the fast track - should be ready in... 2040

[Tupelo3]

Originally Posted by anagirl

I think it is on the fast track - should be ready in... 2040

Ha ha, that's funny Ana, although I don't know if we should laugh or cry!

[zanpar321]

Originally Posted by Tupelo3

Ha ha, that's funny Ana, although I don't know if we should laugh or cry!

You'd think if the folks at NIH really cared, this type of study would be funded by NIH ASAP. Does anyone have any contacts there that could be asked to fund this nasal GDNF study at NIH?

[Lana]

Originally Posted by zanpar321

You'd think if the folks at NIH really cared, this type of study would be funded by NIH ASAP. Does anyone have any contacts there that could be asked to fund this nasal GDNF study at NIH?

I wonder if PD community, people like us can start fundraising campaign to fund early phase.

[zanpar321]

Originally Posted by Lana

I wonder if PD community, people like us can start fundraising campaign to fund early phase.

Great idea Lana. Also, I wonder of Cure Parkinson's Trust UK would consider helping fund such a study on Intranasal GDNF? They are apparently a patient lead organization. Does anyone know a contact there to talk to regarding this?

http://www.cureparkinsons.org.uk/

They are presently funding a GDNF trial for infusing GDNF directly into the brain.

http://www.cureparkinsons.org.uk/gdnf-study-p

GDNF trial study video

http://www.parkinsons.org.uk/content...dnf-parkinsons

[wendy s]

Here is an interim report that I found on MJFF. I couldn't find anything more recent either on MJFF or PubMed.

INTERIM PROGRESS REPORT



Professor Waszczak reported that intranasal administration of GDNF has a neuroprotective efficacy in a pre-clinical model of Parkinson’s disease. Neuroprotection is also achieved by stereotaxic injection of gene vectors expression GDNF into the striatum. Other studies show that 125I-GDNF undergoes receptor mediated retrograde transport from the striatum to the midbrain dopaminergic neuron cell bodies. To distinguish gene-derived from endogenous GDNF, we used a gene vector expressing GDNF with an epitope tag. This gene vector was intranasally administered to test whether the intranasal (gene-derived) GDNF would appear within the midbrain dopaminergic neuron cell bodies.

Significant technical issues, such as delivery losses due to the “sticky” nature of gene vector, prevented reproducible adequate transfection following intranasal administration. While a sensitive histological/immunohistochemical procedure for visualizing trace GDNFflag in intracellular vesicles was developed, further studies are required to properly test whether intranasal, gene-derived, GDNF can make direct contact with receptors expressed by midbrain dopaminergic neurons.

April 2012

[girija]

[QUOTE=zanpar321;1106894]Great idea Lana. Also, I wonder of Cure Parkinson's Trust UK would consider helping fund such a study on Intranasal GDNF? They are apparently a patient lead organization. Does anyone know a contact there to talk to regarding this?

Peggy, who is a member of Neurotalk knows Tom (founder of Cure Parkinons) and might be able to help. I am forwarding this info to Peggy right now.

The links posted here from 2013. Did anyone find more info or current status of the project?

[girija]

Originally Posted by wendy s

Here is an interim report that I found on MJFF. I couldn't find anything more recent either on MJFF or PubMed.

"Significant technical issues, such as delivery losses due to the “sticky” nature of gene vector, prevented reproducible adequate transfection following intranasal administration. While a sensitive histological/immunohistochemical procedure for visualizing trace GDNFflag in intracellular vesicles was developed, further studies are required to properly test whether intranasal, gene-derived, GDNF can make direct contact with receptors expressed by midbrain dopaminergic neurons."

April 2012

Thanks. 2013 report sounds more promising than 2012 report. Lets hope they are making progress. I am sending an email to these researchers requesting the latest info.

girija

[girija]

[PDF]View Poster - Northeastern University
www.northeastern.edu/rise/wp-content/.../Aly.pdf
Northeastern University
Brendan T. Harmon. †. , Mark J. Cooper. §. , Ozge Sesenoglu-Laird. §. , Linas Padegimas. § and Barbara L. Waszczak. †. †. Department of Pharmaceutical ...